GSK receives offer for thrombosis brands
GSK has received an offer from South African pharma company, Aspen, and it's wholly owned subsidiary, Aspen Global Incorporated, for its thrombosis brands and Notre-Dame de Bondeville (NDB) manufacturing site in France.
Aspen and GSK have agreed on a period of exclusivity and GSK will respond to the offer in due course, subject to consultation with employees and the relevant works councils.
While the financial terms have not yet been disclosed, the offer does include the transfer of deep vein thrombosis treatments Arixtra (Fondaparinux Sodium) and Fraxiparine brands (nadroparin) (excluding China, India and Pakistan), which generated approximately £420 million in revenue for GSK in 2012.
Related news:
GlaxoSmithKline PLC GSK receives offer for Thrombosis Brands (Wall Street Journal)
South Africa's Aspen to acquire thrombosis drugs from GSK (Reuters)
Reference links:
